Updated zenocutuzumab data in NRG1+ cancer to be presented at ASCO 2022 More

Closing in
on cancer

At Merus, we have a sense of urgency and a passion to help patients declare victory over cancer.

Our Latest News

Our Pipeline

Multiclonics^® Platform

Careers at Merus

Clinical Trials

Merus Announces Publication of Abstract of Zenocutuzumab in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Merus to Present at the H.C. Wainwright Global Investment Conference

Merus Announces Financial Results for the First Quarter 2022 and Provides Business Update